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Vaccinia virus protein A49 inhibits NF-κB activation by molecular
mimicry and has a motif close to the N terminus that is conserved
in IκBα, β-catenin, HIV vpu and other proteins. This motif contains
2 conserved serines and, for IκBα and β-catenin, phosphorylation
of these serines enables recognition by the E3 ubiquitin ligase
β-TrCP. Binding of IκBα and β-catenin to β-TrCP leads to their
ubiquitylation at upstream lysines and thereafter proteasome-
mediated degradation. In contrast, HIV vpu and VACV A49 lack
these lysines and so are not degraded. This report demonstrates
that A49 is phosphorylated at serine 7, but not serine 12, and that
this is necessary and sufﬁcient for binding β-TrCP and antagonism
of NF-κB activation. Phosphorylation of A49 S7 occurs when NF-
κB signaling is activated by addition of IL-1β, or overexpression of
TRAF6 or IKKβ, the kinase needed for IκBα phosphorylation and
activation of NF-κB signaling. Thus A49 shows beautiful biological
regulation for it becomes an NF-κB antagonist upon activation
of NF-κB signaling. The virulence of viruses expressing mutant
A49 proteins, or lacking A49 (vΔA49), were tested. vΔA49 was
attenuated compared to wild type, as reported previously, but
viruses expressing A49 that cannot bind β-TrCP, or that binds β-TrCP
constitutively, each had intermediate virulence. Therefore, A49
promotes virulence by inhibiting NF-κB activation and by another
unknown mechanism independent of S7 phosphorylation and NF-
κB antagonism. Lastly, a virus lacking A49 was a more potent
vaccine than wild type virus.
Vaccinia virus j nuclear factor kappa B j virus immune evasion j innate
immunity
Introduction
Vaccinia virus (VACV) is a member of the Orthopoxvirus genus
of the Poxviridae (1). Like other poxviruses, VACV has a large,
complex virion, a cytoplasmic site of replication (2) and a dsDNA
genome encoding about 200 genes (3). Orthopoxvirus genomes
have a highly conserved central region and more variable termini
(4). The central region encodes proteins needed for replication,
whilst the terminal regions encode proteins that affect virus
virulence, host range and immunomodulation. Many of the lat-
ter proteins are dispensable for replication in cell culture, but
suppress innate immunity and are important in vivo (5). These
immunomodulatory proteins are numerous and many target the
same signaling pathway. For instance, VACV encodes at least ten
proteins that inhibit activation of nuclear factor kappa B (NF-κB)
(5, 6). This article concerns one NF-κB inhibitor, protein A49.
A49 is a small intracellular protein that contributes to virus
virulence (7). A49 has a B cell lymphoma (Bcl)-2-like fold (8) and
is one of 11 Bcl-2-like proteins encoded by VACV. Some of these
mimic cellular Bcl-2 family proteins with anti-apoptotic activity.
For instance, proteins N1 (9-11) and F1 (12) inhibit apoptosis
(10, 11, 13, 14). However, VACV Bcl-2 proteins B14, A52 (15)
and A46 (16, 17) do not inhibit apoptosis, but inhibit other innate
immune signaling pathways (18-22). A49 most closely resembles
myxoma virus protein M11, an anti-apoptotic protein (23), but
does not bind the cellular pro-apoptotic Bcl-2 proteins bound by
M11 (8).
A49 inhibits activation of the interferon (IFN)-β promoter (7)
by blocking NF-κB signaling via molecular mimicry (7). Near its
N terminus, A49 contains 2 serines that are conserved in several
proteins, such as IκBα and β-catenin (24), and as viral proteins
HIV vpu (25, 26) and rotavirus non-structural protein 1 (NSP1)
(27). For IκBα, these serines are phosphorylated by IKKβ that
is activated during NF-κB signaling. Once phosphorylated, IκBα
is recognised by the E3 ubiquitin ligase, beta-transducin repeat-
containing protein (β-TrCP) (24), which ubiquitylates upstream
lysine residues leading to proteasomal degradation of IκBα (28).
This releases the NF-κB subunits p65 and p50 into the nucleus.
A49 binds to β-TrCP and prevents ubiquitylation of phospho-
rylated (p)-IκBα and thereby stabilises it (7). A49 also stabilises
another β-TrCP substrate, β-catenin, leading to activation of the
wnt signaling pathway (29). The interaction of A49 with β-TrCP
requires either or both of serines 7 and 12 for mutation of both
residues to alanine prevented binding to β-TrCP and NF-κB
antagonism (7). In contrast, mutation to glutamic acid enhanced
binding to β-TrCP and increased NF-κB antagonism, suggesting
A49 needs phosphorylation to be an NF-κB inhibitor.
Here A49 is shown to be phosphorylated on S7, but not S12,
and this is necessary and sufficient for binding to β-TrCP and
antagonism of NF-κB activation. Further, A49 is phosphorylated
when NF-κB signaling is activated. Therefore, A49 functions
to inhibit NF-κB signaling conditionally, when this signaling
pathway is activated. VACVs expressing mutant A49 unable to
bind β-TrCP and antagonise NF-κB signaling, or expressing A49
binding β-TrCP constitutively, each had intermediate virulence
between WT virus and a virus lacking the A49R gene (vΔA49).
This indicates that A49 promotes virulence by inhibiting NF-κB
activation and another function. Lastly, a VACV lacking A49 was
more immunogenic thanWT virus and provided better protection
against VACV challenge.
Signiﬁcance
Vaccinia virus (VACV) encodes many proteins that inhibit the
innate response to infection. One example is protein A49 that
inhibits NF-κB activation by binding to the E3 ligase β-TrCP.
Here we show that A49 is phosphorylated on serine 7 and
that this is necessary for binding β-TrCP and inhibition of NF-
κB activation. Further, this phosphorylation occurs when the
NF-κB pathway is stimulated and the kinase IKKβ is activated.
Thus, A49 shows beautiful biological regulation, for activation
of the pathway activates the virus inhibitor of the pathway.
The signiﬁcance of this is seen in vivo. For VACVs expressing
A49 S7A or S7E are less virulent than wild type virus but more
virulent than a virus lacking A49.











































































































































Fig. 1. A49 is phosphorylated upon stimulation of NF-κB signaling. HeLa cells
were transfected with codon-optimised, FLAG-tagged wildtype A49 (WT) or
A49 mutant S7/12A (S/A) or an empty vector (EV) control. After 24 h, cells
were stimulated for 30 min with 50 ng/ml IL-1β, or left unstimulated, before
lysis in 50 mM Tris pH 7.4, 250 mM NaCl, 0.5% NP-40, supplemented with
protease inhibitors and NaF. Cleared lysates were mixed with SDS loading
buffer, boiled and analysed immediately by Phosphate afﬁnity PAGE, to
separate phosphorylated (p+) from unphosphorylated (p-) A49, and regular
PAGE, followed by immunoblotting.
Fig. 2. Phosphorylated A49 is protected from de-phosphorylation by β-
TrCP. HEK-293T cells were transfected with codon-optimised, myc-tagged
wildtype A49 (WT) or A49 mutant S7/12A (S/A) and FLAG-tagged β-TrCP or
TRAF6. Cells were lysed in Phosgel lysis buffer supplemented with protease
inhibitors and NaF and treated with Lambda protein phosphatase (LPP)
or not as indicated. Samples were then mixed with SDS loading buffer,
boiled and analysed immediately by Phosphate afﬁnity PAGE, to separate




The cellular proteins β-catenin and IκBα are phosphory-
lated to enable efficient binding to β-TrCP, and the structure of
β-TrCP bound to p-β-catenin shows extensive interactions be-
tween the phosphate groups of β-catenin and the β-TrCP binding
pocket (30). To examine if A49 is also phosphorylated, a phos-
tag was introduced into polyacrylamide gels as described (31).
Phosphorylated proteins bind the phos-tag and so migrate more
slowly during gel electrophoresis. Plasmids expressing codon-
optimised, FLAG-tagged, WT A49, or in which serines 7 and 12
are changed to alanines (S7/12A) (7), were transfected into HeLa
cells in parallel with empty vector (EV). These cells were left
untreated or treated with interleukin (IL)-1β before harvesting
and analysis by phosphate affinity PAGE and regular SDS-PAGE
and immunoblotting (Fig. 1). The level of WT and mutant A49
Fig. 3. . A49 is phosphorylated on serine 7, but not serine 12. HEK-
293T cells were transfected with codon-optimised, myc-tagged wildtype A49
(WT) or A49 mutants and FLAG-tagged TRAF6. Cells wer lysed in IP buffer
(Methods) and cleared cell lysates were mixed with SDS loading buffer,
boiled and analysed immediately by Phosphate afﬁnity PAGE, to separate
phosphorylated (p+) from unphosphorylated (p-) A49, and regular PAGE. The
star marks a non-speciﬁc signal detected by the anti-FLAG antibody.
detected by anti-FLAG antibody were similar with or without
IL-1β stimulation (bottom). However, the phosphate affinity gel
showed a slower migrating band that was present with WT A49
protein, but not S7/12A, and only after IL-1β stimulation (Fig.
1 top). Compared to the non-phosphorylated A49 protein, the
phosphorylated (p)-A49 band is weak, suggesting only a small
fraction of A49 is phosphorylated, or that, in the absence of
binding partner, it is de-phosphorylated.
To confirm this extra band is p-A49, samples were treatedwith
phosphatase (LPP). In this case, myc-taggedWT and S7/12Amu-
tantA49were expressed inHEK-293T cells, together with FLAG-
tagged β-TrCP. In parallel, WT A49 was transfected either alone
or with FLAG-tagged TRAF6 to activate NF-κB signaling. SDS-
PAGE showed expression of FLAG-tagged β-TrCP or TRAF6,
and myc-tagged A49 proteins (Fig. 2 bottom). In the phosphate
affinity gel, there was a slower migrating A49 band, seen only
when the pathway was activated by TRAF6 (compare lanes 1
and 5), and treatment with LPP caused loss of this band (lane
6). When β-TrCP was overexpressed, p-A49 was seen without
pathway stimulation and was resistant to de-phosphorylation,
suggesting A49 - β-TrCP interaction is stable and protects p-
A49 from de-phosphorylation (lanes 2 and 3). The stabilisation
induced by β-TrCP overexpression may explain why p-A49 was
detectable without addition of IL-1β or expression of TRAF6 to
activate the pathway.
A49 is phosphorylated on serine 7 only
To investigate which serines are phosphorylated, additional
mutant A49 proteins were constructed. These comprised S7A,
S12A, and also S7E, S12E and E11A. S7E and S12E were in-
cluded because, previously, a mutant A49 with both these serines
mutated to glutamic acid (S7/12E) bound to β-TrCP strongly
and was a stronger inhibitor of NF-κB activation (7). E11A was
included because, compared to IκBα, A49 contains an extra aa
prior to S12. Since this residue is glutamic acid, a phospho-
mimetic, this might substitute for a phospho-serine at S12. WT
and mutant myc-tagged A49 alleles were transfected into cells to-
gether with FLAG-tagged TRAF6 and cell lysates were analysed
as above (Fig. 3). SDS-PAGE showed the expression and slightly
differing electrophoretic mobility of these mutants (lower panel).
The phospho-affinity gel showed a p-A49 band with WT, S12A,
S12E and E11A, but not with S7/12A, S7A, or S7E (Fig. 3 top).
Therefore, S7 but not S12 is phosphorylated.
Phosphorylation of A49 is needed for binding β-TrCP and











































































































































Fig. 4. . p-A49 co-immunoprecipitates with β-TrCP. A) HEK-293T cells
were transfected with FLAG-tagged β-TrCP and untagged, codon-optimised
wildtype A49 (WT) or its mutants. Cells were lysed after 24 h in IP buffer
supplemented with protease and phosphatase inhibitors and cleared lysates
were incubated for 16 h with a FLAG-afﬁnity gel. Bound proteins were
washed with lysis buffer and eluted with SDS loading buffer before they
were analysed by immunoblot, together with the whole cell lysate (WCL). B)
HEK-293T cells were transfected with plasmids expressing either myc-tagged
GFP, or myc-tagged β-TrCP. After 24 h, the cells were infected at 5 p.f.u./cell
with the indicated VACVs for 16 h. Cells were then treated as in A), with the
exception that a myc-afﬁnity gel was used.
The ability of these A49 mutants to bind β-TrCP and inhibit
NF-κB signaling was tested. HEK-293T cells were transfected
with FLAG-tagged β-TrCP and untagged, codon-optimised WT
A49 or mutants. The FLAG-tagged β-TrCP was immunoprecip-
itated from cell lysates and analysed by immunoblotting with
anti-FLAG and anti-A49 polyclonal antibody (7) (Fig. 4A). Note
the slightly different electrophoretic mobility of these untagged
A49 proteins compared to the myc-tagged A49 proteins shown in
Figure 3. All mutants with S7, or S7E, were immunoprecipitated
by β-TrCP, and all mutants lacking S7 (or S7E) were not, or
only very poorly. Thus S7 phosphorylation, or E at this position,
is needed for binding β-TrCP. Similar analyses in which myc-
tagged β-TrCP ormyc-taggedGFPwere transfected into cells that
subsequently were infected with WT or A49 mutant viruses, also
showed that WT A49 or A49 S7/12E were co-precipitated with β-
TrCP, whereas A49 Δ12 or A49 S7/12A were not (Fig. 4B). Equal
Fig. 5. Mutation of serine 7 abolishes inhibition of NF-κB activation by A49.
A) HEK-293T cells were transfected with NF-κB-luc, TK-Renilla and plasmids
encoding WT or mutant A49 proteins, or EV. After 24 h cells were stimulated
by addition of 15 ng/ml TNFα for 8 h. Luciferase activity was measured
in cell lysates. Triplicate samples were analysed for each condition. Data
are expressed as the mean fold induction of the ﬁreﬂy luciferase activity
normalised to renilla values for the stimulated versus unstimulated samples.
Data are then expressed as the EV value compared to the test sample +/-
Standard error of the mean. ** p<0.01, * p< 0.05, ns not, signiﬁcantly
different. B) Immunoblot showing the expression levels of A49 and α-tubulin
analysed in A).
infection and equal loading were shown using antibody to VACV
protein D8 or α-tubulin, respectively.
The ability of A49 mutants to block NF-κB activation was
measured using a NF-κB responsive promoter linked to lu-
ciferase, as described (7). WT A49 and mutants S12A, S7E,
S12E, S7/12E and E11A all inhibited NF-κB activation, but S7A,
S7/12A, S7/E11A and a mutant lacking the first 12 aa (Δ12)
did not (Fig. 5A). Immunoblotting of cell lysates with anti-A49
antibody and anti-α-tubulin confirmed equivalent expression of
these proteins and equal loading (Fig. 5B). In summary, the
phosphorylation of A49 occurs at S7 and this is critical for A49
to bind β-TrCP and antagonise NF-κB signaling.
IKKβ can phosphorylate A49
Stimulation of NF-κB signaling via addition of IL-1β, or
overexpression of TRAF6 caused phosphorylation of A49 (Figs. 1
& 2). Both stimuli cause phosphorylation and activation of IKKβ
leading to phosphorylation of IκBα. Under these conditions, A49
was phosphorylated, suggesting that IKKβ might phosphorylate
A49. To test this, cells were transfected with myc-tagged A49
together with FLAG-tagged TRAF6, IKKα, IKKβ or NEMO and
cell lysates were analysed by SDS-PAGE or phosphate affinity
PAGE (Fig. 6). SDS-PAGE confirmed expression of all these
proteins, except for IKKα, that was barely detectable. Phospho-
affinity PAGE showed that expression of IKKβ induced strong
phosphorylation of A49 and that TRAF6 was less effective. Trace
amounts of p-A49 were also seen with low expression of IKKα,
but no phosphorylation of A49 was observed when NEMO was











































































































































Fig. 6. A49 is phosphorylated after activation of NF-κB signaling at or down-
stream of the IKK complex. HEK-293T cells were transfected with codon-
optimised, myc-tagged A49 alone or together with FLAG-tagged TRAF6,
IKKα, IKKβ or NEMO. As a control cells were co-transfected with the S7/12A
mutant of A49 and IKKβ. Cells were lysed in Phos-gel buffer supplemented
with NaF and cleared lysates were mixed with SDS loading buffer, boiled
and stored at ‑80 °C before analysis by Phosphate afﬁnity PAGE, to separate
phosphorylated (p+) from unphosphorylated (p-) A49, and regular PAGE.
mutant confirmed lack of A49 phosphorylation even when IKKβ
was expressed. In summary, IKKβ can induce phosphorylation of
A49.
VACV expressing non-phosphorylated A49 is less virulent
than wild type virus
A virus mutant lacking gene A49R, vΔA49, was attenuated
in a murine intranasal model (7). To determine if the ability of
A49 to bind β-TrCP and so inhibit NF-κB signaling is the only
reason for attenuation, recombinantVACVs bearingA49 S7/12A,
S7/12E or lacking the first 12 aa (Δ12) were constructed and the
virulence of these viruses was tested by measuring weight change
after infection (Fig. 7A). Notably, all these mutant viruses had
intermediate virulence that was statistically different from both
WT and deletion mutant. For the A49 S7/12E mutant virus, the
mutant A49R gene was replaced with the WT gene (A49 S7/12E-
rev). The virulence of this virus was the same as WT (Fig. 7B),
confirming that the intermediate virulence of the S7/12E virus
was due to A49 mutation. For the other mutant viruses (S71/12A
and Δ12), additional revertant viruses were not made, but instead
complete genome sequencing confirmed that there were no other
mutations compared to WT. Collectively, these analyses showed
that A49 binding to β-TrCP and thereby inhibiting NF-κB is im-
portant for virulence. However, because viruses with mutant A49
proteins unable to inhibit NF-κB were more virulent that vΔA49,
A49 has an additional function that contributes to virulence. Sur-
prisingly, the virulence of the A49 S7/12E mutant virus was also
intermediate. This A49 protein binds β-TrCP and inhibits NF-κB
signaling at least as efficiently as WT A49 (7) and yet the virus
has reduced virulence. A possible explanation is binding β-TrCP
constitutively, whether or not the NF-κB pathway is activated.
This might prevent non-phosphorylated A49 unbound by β-TrCP
from having another function. This would be consistent with the
observation that a virus expressing A49 that cannot bind β-TrCP
has intermediate virulence.
Deletion of A49 increases VACV immunogenicity
In several cases loss of one immunomodulator from VACV
increases virus immunogenicity despite virus attenuation. To in-
vestigate if this was true for A49, mice immunised with vA49WR
or vΔA49 were challenged intranasally 42 d later with WT VACV
strain WR. Animals immunised with vΔA49 had significantly
lower weight loss compared to WT virus (Fig. 7C). The viruses
with mutated A49 proteins were intermediate between WT and
vΔA49, but these small differences did not reach statistical signif-
icance (Supplementary Figure 1).
Discussion
This article reports that VACV protein A49 is phosphorylated
on serine 7 when the NF-κB signaling pathway is turned on.
Addition of IL-1β, or overexpression of TRAF6 or IKKβ, caused
A49 phosphorylation and this enabled p-A49 binding to β-TrCP.
Sequestration of β-TrCP by p-A49 prevents β-TrCP recognizing
other substrates such as p-IκBα (7) or p-β-catenin (29) so they
remain stable. β-TrCP has several other substrates, for instance
CDC25 (32), that might also be affected. For β-catenin, its stabil-
isation leads to activation of thewnt signaling pathway (29). For p-
IκBα, its stabilisation causes retention of cytoplasmic NF-κB p65
and p50 and no transcription from NF-κB dependent promoters.
Since the ability of A49 to bind to β-TrCP is dependent on
phosphorylation, and phosphorylation can be achieved by IKKβ
activation, the activation of NF-κB signaling is a turn on for A49
to turn off NF-κB activation. This represents beautiful biological
regulation for without the need to inhibit NF-κB, A49 remains
unbound to β-TrCP and free to undertake other function(s).
In vivo evidence indicates that A49 has a second function.
The virulence of VACV expressing mutant A49 that is not phos-
phorylated, no longer binds β-TrCP and no longer inhibits NF-κB
activation, is intermediate between WT and vΔA49. If inhibiting
NF-κB activation was the sole function of A49, a virus expressing
A49 unable to be phosphorylated would likely have virulence
equivalent to vΔA49. Analysis of VACV expressing A49 S7/12E
provides further evidence for another A49 function. A49 S7/12
binds β-TrCP constitutively, but despite this, VACV expressing
S7/12E A49 is attenuated compared to WT. This attenuation
may arise from A49 being constitutively bound to β-TrCP and so
unable to bind to other substrates and mediate other functions.
An alternative hypothesis, that transient early activation of NF-
κB is beneficial for the virus, seems less likely because the virus
expresses many other NF-κB inhibitors early after infection.
Possible other functions for A49 include bringing other sub-
strates to β-TrCP for ubiquitylation and proteasomal degradation,
rather as HIV Vpu induces degradation of CD4 (26). Such func-
tion would be lost by mutation of A49 to prevent β-TrCP binding.
Alternatively, A49 might bind to other substrates without induc-
ing their degradation to inhibit or modify their function. Some
rotavirus NSP1 proteins bind to β-TrCP and modify its function
like A49, whereas other NSP1 proteins induce degradation of β-
TrCP (as well as IRF3 and IRF7) (33). Further proteomic screens
for additional A49 binding partners either in the presence of
proteasomal inhibitors, or using A49 mutants unable to bind β-
TrCP are needed to identify other targets.
A49 is one of several virus proteins that contain the motif
SXXXS and mimic cellular proteins with this motif. Such virus
proteins include HIV vpu (26), Epstein-Barr virus latent mem-
brane protein 1 (34) and the NSP1 protein from some rotavirus
strains (33). These viral proteins, like the cellular counterparts,
are phosphorylated and thereafter are recognized by β-TrCP.
The cellular proteins such as IκBα and β-catenin contain ly-
sine residues just upstream of the SXXXS motif and these are
ubiquitylated by β-TrCP leading to proteasomal degradation.
This phosphorylation, ubiquitylation and degradation are cellular
mechanisms to control activation of the NF-κB and wnt signaling
pathways. In contrast, the virus proteins lack upstream lysines and
so are not ubiquitylated following phosphorylation and remain











































































































































Fig. 7. Virulence and immunogenicity of VACV A49 mutant viruses. A) Female Balb/c mice (6-8 weeks old, n=5) were infected intranasally with 5 × 103 p.f.u.
of the indicated viruses (10 µl / nostril) and their weight was monitored daily. Weight data are expressed as the percentage ± SEM of the mean weight of the
same group of animals on day 0. Statistical analyses compared each mutant virus with each other and with vA49 and vΔA49 viruses using 2-way ANOVA. B) As
in A) except using VACV WT (A49WR), A49 S7/12E (A49 S/E), ΔA49, and A49 S7/12E-rev (A49 S/E-rev). A49WR and A49 S/E-rev were not statistically different.
C) Mice immunised with VACV WT or ΔA49 were challenged i.n. with 1 × 107 p.f.u. of wild-type VACV WR at 42 d p.i. Mice were monitored as in A). Statistical
analyses using 2-way ANOVA showed the difference between these two groups was signiﬁcant; p=0.012. Data shown in A) and C) are from one representative
experiment out of two and in B) are from a single experiment.
A49 differs from some other β-TrCP substrates in being
phosphorylated on only one of the two serines (S7) and this
is sufficient for binding β-TrCP. In contrast, phosphorylation of
p105 on both serines 927 and 932 is needed for recognition by β-
TrCP and subsequent degradation (35). Other β-TrCP substrates
can be recognized without phosphorylation (36). In cases where
phosphorylation is needed for binding to β-TrCP, the kinases
mediating phosphorylation may differ. For instance, HIV Vpu
is phosphorylated by casein kinase-2 (CK-2) at S52 and S56
(37), whereas IKKβ can induce phosphorylation of VACV A49,
although other kinases may also do so. Exactly how p-A49 fits into
the IκBα-binding pocket of β-TrCP is unknown, but phosphory-
lation of S7 is essential and a phospho-mimetic residue at S12
is tolerated. A49 differs from most cellular and viral proteins in
containing an extra residue between the 2 serines, and shares this
property with p105. Removal or substitution of this residue does
not prevent binding to β-TrCP.
Overexpression of β-TrCP, increased p-A49 levels without
activation of NF-κB signaling by upstream stimuli. This suggests
that some A49 phosphorylation may occur without pathway acti-
vation, due to constitutive low IKKβ activity or activity of other
kinases, and that p-A49 is stabilized by binding β-TrCP. Consistent
with this, A49 is resistant to de-phosphorylation when β-TrCP
is overexpressed. In contrast, at endogenous β-TrCP levels, A49
may be dephosphorylated by phosphatases, so only a small frac-
tion of A49 is phosphorylated in steady state.
Lastly, A49 is one of more than 10 VACV proteins that all in-
hibit NF-κB activation, and which when deleted individually from
VACV cause an in vivo phenotype (5). Intuitively, attenuation
from loss of an inhibitor seems improbable if 10 other inhibitors
remain. A possible explanation for this paradox is that these NF-
κB inhibitors are multi-functional and the other function(s) are
not compensated by the other NF-κB inhibitors. For instance, N1
inhibits NF-κB activation and apoptosis (10, 11), and evidence for
more than one function for A49 is presented here.
In conclusion,VACVproteinA49 is phosphorylated on serine
7 and this is required for binding to β-TrCP and inhibition of NF-
κB signaling. Viruses expressing A49 unable to bind to β-TrCP,
or that bind β-TrCP constitutively, have virulence intermediate
betweenWT and A49 deletion mutant. Thus A49 is a conditional
inhibitor of NF-κB and is only activated when needed, namely
when NF-κB signalling is activated.
Materials and Methods
Cells
HEK-293T cells BSC-1 cells were grown in DMEM (Gibco) supplemented
with 10% heat-treated (56 °C, 30 mins) fetal bovine serum (FBS, Harlan-
Sera Lab), 100 U/ml penicillin and 100 µg/ml streptomycin (P&S). HeLa cells
and RK13 cells were grown in mimimum essential medium (MEM, Gibco)
supplemented with 10% FBS and P&S. HeLa cells were also supplemented
with non-essential aa (Gibco).
Viruses
Vaccinia virus (VACV) strain Western Reserve (WR) and derivatives lack-
ing the A49R gene, vΔA49, or in which the A49R gene was re-inserted
into vΔA49, vA49-Rev, were described (7). Additional VACVs expressing
mutant A49 proteins were constructed by transient dominant selection (38)
as described for vA49-Rev (7) using plasmids bearing mutant A49R alleles.
Viruses were grown on RK13 cells and titrated by plaque assay on BSC-1 cells.
For in vivo work, viruses were puriﬁed from cytoplasmic extracts of infected
cells by sedimentation through a cushion of 36% (w/v) sucrose (39).
Codon optimisation and site-directed mutagenesis
A version of gene A49R codon-optimised for expression in human cells
was purchased from Thermo Fisher Scientiﬁc. Mutations in either the WT
A49R gene for expression from VACV, or the codon-optimised A49R gene
for expression in mammalian cells, were made using the QuickChange ®
Site-Directed Mutagensis Kit (Agilent). Changes were conﬁrmed by DNA
sequencing.
Reporter gene assays
Reporter gene assays in HEK-293T cells using NF-κB-ﬁreﬂy luciferase and
TK-renilla were done as described (7). These plasmids were transfected into
cells together with plasmids expressing WT or mutant A49 proteins and the
following day cells were stimulated with TNF or IL-1β (as indicated) and
the levels of luciferase activity determined. The fold induction of luciferase
activity following pathway stimulation (normalised to renilla control) were
calculated compared to unstimulated control. Statistical analyses compared
the fold induction with empty vector (EV) to test sample.
Genome sequencing
DNA was extracted from viruses that had been puriﬁed from infected
cells by sedimentation through 2 sucrose cushions (36% w/v) and the com-
plete genome sequence was determined by Illumina technology. The VACV-
A49-S/A DNA gave 232,436 reads with a mean coverage density of 273 per
nucleotide, the VACV-A49Δ12 had 294,154 reads with a mean coverage of
423, and the WT-VACV was also sequenced with 401,667 reads and a mean
coverage of 556.
Mobility shift detection of phosphorylated proteins
HEK-293T cells were transfected and or stimulated as described in ﬁgure
legends. Prior to harvest, cells were washed with PBS on ice, scraped into
1 ml PBS, collected by centrifugation at 500 g for 5 min at 4 °C and then
lysed in 180 µl Phosgel lysis buffer (20 mM Tris-HCl pH 7.4, 140 mM NaCl,
10 mM CaCl2, 0.1% Triton X-100) with 10 mM NaF (New England Biolabs) if
phosphatase treatment was performed. After 15 min on ice, the lysate was
cleared by centrifugation at 18,845 g for 20 min at 4 °C and the supernatant
was mixed with 6 x loading buffer (ﬁnal concentration 50 mM Tris-HCl [pH
6.8], 2% SDS, 10% glycerol, 0.1% bromophenol blue) and either stored at -80
°C or analysed immediately by SDS- PAGE.
Phosphate afﬁnity SDS-PAGE
Polyacrylamide gels were prepared with Bis-Tris/HCl buffer at pH 6.8
(31) and addition of Phos-tag™ acrylamide (40). Separating gels (10% acry-
lamide) were made with 357 mM Bis-Tris-HCl, 50 mM Phos-tag acrylamide
and 100mMZn(NO3)2 and stacking gels (4%acrylamide)weremadewith 357
mM Bis-Tris-HCl, without Phos-tag or Zn(NO3)2. For the running buffer, fresh
1 M sodium bisulphite (Sigma) solution was prepared, ﬁltered and mixed
with 20 x MOPS buffer prior to electrophoresis to give ﬁnal concentrations
of 50 mM MOPS, 50 mM Tris, 0.1% (w/v) SDS and 5 mM sodium bisulphite.
Immunoblotting of Phos-tag™ gels
After electrophoresis the gel was twice soaked in NuPAGE® transfer
buffer (Thermo Scientiﬁc) supplemented with 10% (v/v) methanol and 5
mM sodium bisulphite for 15 min. Transfer and subsequent procedures were
the same as described (7). The antibodies used for immunoblotting and the
positions of molecular mass markers (kDa) are indicated on the ﬁgures.
Phosphatase treatment of cell lysates
Cell lysates (39 µl), prepared as above, were mixed with 5 µl MnCl2 (New
England Biolabs) and 5 µl 10 x PMP buffer (New England Biolabs). Samples
that were lysed in the absence of NaF also received 1 µl lambda protein











































































































































min, 6 x SDS loading buffer was added and samples were analysed by Phos-
tag PAGE.
Immunoprecipitation
Cells were lysed in IP buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 10
mMCaCl2, 0.1%NP-40, 10%glycerol) supplementedwith protease inhibitors
(cOmplete EDTA-free, Roche) and phosphatase inhibitors (PhosSTOP, Roche)
where indicated. Lysates were cleared by centrifugation and then incubated
with anti-FLAG M2 afﬁnity resin (Sigma) at 4 °C for 4 h or with anti-c-Myc
agarose resin (Santa Cruz) at 4 °C overnight, washed 4 times with lysis buffer,
mixed with protein loading buffer and analysed by SDS-PAGE.
Antibodies and cytokines
The following antibodies were used: rabbit polyclonal anti-A49 (diluted
1:1,000) (7), mouse monoclonal AB1.1 against VACV protein D8 (diluted
1:1,000) (41), rabbit polyclonal anti-FLAG (diluted 1:1,000) (Sigma-Aldrich
F7425), mouse monoclonal anti-myc (diluted 1:1,000) (Cell-Signaling (B11),
mouse monoclonal anti-α-tubulin (diluted 1:1,000) (Millipore DM1A). TNFα
and IL-1β were purchased from Peprotech.
In vivo experiments in murine models
VACV was puriﬁed from cytoplasmic extracts of infected cells by two
rounds of sedimentation through 36% (w/v) sucrose at 32,900 g for 80 min.
Virus was re-suspended in 10 mM Tris-HCl pH 9 and stored at -80 °C. Virus
used for infections was diluted in PBS containing 1% bovine serum albumin
and the titer of the diluted virus that was used to infect mice was determined
by plaque assay on the day of infection. Female BALB/c mice (n = 5, 6-8 weeks
old)were anaesthetised and inoculated intranasally (i.n.) in both nostrils with
5 × 103 p.f.u. and the bodyweightwasmeasured daily thereafter (42). For the
challenge experiments, mice that had been immunised i.n. were challenged
i.n. 6 weeks later with 1 × 107 p.f.u. of wild-type VACV WR. Mice were
monitored daily to record body weight.
Statistical analysis
Data were analysed using an un-paired Student’s t-test, with Welch’s
correction where appropriate, or a two-way ANOVA test where appropriate
using the GraphPad Prism statistical software (GraphPad Software, San
Diego, CA). Statistical signiﬁcance is expressed as follows: *P < 0.05, **P
< 0.01, ***P < 0.001. Data are representative of at least 2 independent
experiments.
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